Abstract
Protease inhibitor (PI) therapy may be associated with adverse events. Switching the PI component to a non-PI may reduce some side-effects, but the immune effects are unclear. In a meta-analysis using strict inclusion criteria, a randomized switch from PI was associated with impaired CD4 T-cell gains compared with maintaining PI (PI arm +32 cells, effect size 0.130, P = 0.05). Therefore, PI-based therapy results in superior CD4 T-cell gains compared with switching to a non-PI regimen.
Original language | English (US) |
---|---|
Pages (from-to) | 693-695 |
Number of pages | 3 |
Journal | AIDS |
Volume | 18 |
Issue number | 4 |
DOIs | |
State | Published - Mar 5 2004 |
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
- Infectious Diseases